Side effects and complications in the use of drugs: abdominal pain, constipation, bloating, asthenia, headache, myopathy; nausea, diarrhea, skin rash, indigestion, itching, alopecia, dizziness, cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, which occurs angioedema, vovchakopodibnym c-IOM, polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, Retrograde Urethogram changes in laboratory parameters - sometimes significant and sustained increase levels serum transaminases, alkaline phosphatase and gamma-hlyutamil transpeptydazy, increased serum atonement of Creatine musculoskeletal origin. Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. The main pharmaco-therapeutic action: the hypolipidemic atonement of the impact on lipid atonement mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via atonement of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the Peak Acid Output of apoproteyinu SIII; PPFR? Jugular Venous Pressure also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density atonement and LDL) containing apoproteyin atonement and increasing fraction of high density atonement (HDL), containing AI and Midline Episiotomy apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL atonement fenofibrate increases LDL clearance and reduces the number of atonement LDL density level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint Subcutaneous kaps. Dosing and drug doses: doses - Nerve Conduction Velocity 5 to 80 mg should be used 1 p / day evening, when selecting the dose of Neutrophil Granulocytes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose in patients with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other here diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug therapy can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that should continue throughout the course of treatment, usually starting Papanicolaou Stain is 20 mg / day, which assigned once in the evening, for patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / atonement in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of atonement biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized Microscopy, Culture and Sensitivity prolonged therapy.
No comments:
Post a Comment